newsfilter
← Latest News
GlobeNewswire·

Exagen Inc. Reports First Quarter 2026 Results

  • Exagen Inc. reported financial results for the quarter ended March 31, 2026, recording revenue of $17.3 million, a 12% increase from the same period in 2025.
  • The company achieved a gross margin of 59.0% \& reported an operating loss of $3.4 million compared to $3.4 million in the prior year quarter.
  • Net loss for the quarter was $4.0 million, while adjusted EBITDA loss improved to $2.2 million, representing a 14% reduction from the previous year.
  • Trailing-twelve-month average selling price for the AVISE CTD test rose to $444 per test, up 6% from $419 in the prior year.
  • AVISE CTD test volume grew by 10% in the first quarter of 2026 compared to the first quarter of 2025.
  • Cash \& cash equivalents totaled $21.5 million at the end of the quarter, up significantly from $11.2 million in the prior year period.
  • Full-year 2026 revenue guidance remains unchanged at $70 million to $73 million.
  • The company announced a conference call scheduled for May 11, 2026, at 8:30 a.m. ET to discuss the results, with a replay available until May 25, 2026.
  • Exagen Inc. operates as a provider of autoimmune diagnostics based in San Diego County, California, focusing on the AVISE® CTD testing portfolio.